FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2212292700> ?p ?o ?g. }

• W2212292700 abstract "Abstract Introduction Primary plasma cell leukemia (pPCL) is a rare form of plasma cell malignancy with poor prognosis (usually less than 12 months survival with conventional chemotherapy). Only one prospective study with Lenalidomide-Dex before high dose therapy has been recently reported1. Bortezomib-based regimens and high dose Melphalan/ autologous stem cell transplantation (HDM/ASCT) have shown promising results in small retrospective studies. We report here the first prospective multicenter phase II trial for pPCL patients (pts) treated with Bortezomib-Doxorubicine-Dexamethasone (PAD) / Bortezomib-Cyclosphosphamide-Dexamethasone (VCD) as induction before HDM/ASCT. With the aim to improve response and survival, allograft or second ASCT plus consolidation/maintenance with Lenalidomide-Bortezomib-Dex (VRD) were proposed. Patients and method Non-previously treated pts with a diagnosis of pPCL were enrolled in this phase II study of the IFM group from April 2010 to July 2013. PAD (dexa 40 mg + bortezomib 1,3 mg/m2 on day 1, 4, 8, 11 + doxorubicine 30 mg/m2 day 4) and VCD (dexa + bortezomib + cyclophosphamide 300 mg/m2 day 1, 8) were administrated alternatively each 21 days for 4 cycles. For responding patients with circulating plasma cell < 1%, peripheral stem cells were collected after Cyclophosphamide + G-CSF. Either (i) double HDM/ASCT was performed followed by consolidation/maintenance íVDR (dexa 40mg + bortezomib 1,3 mg/m2 on day 1, 4, 8, 11 + lenalidomide 15 mg day 1-15) each 3 months and Lenalidomide 15 mg 21/28 days on others months, for 1 yearý or (ii) tandem HDM/ASCT-reduced intensity conditioning-allograft if there were < 66 years-old. Primary end-point was progression free survival (PFS); secondary end-points were responses rates, overall survival (OS), feasibility, and toxicity. We evaluated the disease response to therapy with the IMWG criteria and the percentage of circulating plasma cells; minimal residual disease (MRD) was evaluated during follow-up. Peripheral circulating plasma cells and bone marrow plasmocytes were collected at diagnosis for centralized FISH and SNP array analysis. Results 40 pts were enrolled with a median age of 55y (27-71). Median follow-up was 12.6 months (7.6-24.8). At diagnosis, the median number of circulating plasma cell was 5.2 G/L (1.3-66). Twenty-two percent had creatinine clearance < 50 ml/min, and 11% < 30 ml/min, 44% had an ISS score of 2 and 37% ISS 3. After induction 35 pts are evaluable. In the intent to treat analysis, 25 (72%) responded (VGPR+CR 37%, PR 28%, SD 5%) and 10/35 (28%) were refractory (pts having circulating plasma cell ≥ 1%) and did not continue the study. Twenty-three of the 25 responding pts underwent HDM/auto and 20 pts are evaluable at 3 months: CR+VGPR 14/20 (70%), PR 4/20 (20%), 1/20 (5%) and PD 1/20 (5%). Second HDM/auto was performed in 6 pts and allograft in 12. Ten of the 14 (72%) evaluable pts achieved VGPR or better and 4/14 (28%) PR. Six pts are currently on consolidation/maintenance phase with VRD. Median PFS was 17.8 months. Median OS was not reached. Genomic data are shown in Table I. MDR evaluation will be presented later. Major toxicities were hematological and infections. Eight pts died: 5 during induction, 1 at HDM/ASCT and 2 post allograft while in relapse. Of note, 2 pts had meningeal involvement at relapse. Conclusion This first large study for pPCL patients with PAD/VCD as induction and HDM/ASCT is effective and induce high responses rates. Consolidation with Allograft or bortezomib-lenalidomide-dex is currently investigated. 1Musto P et al. Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract2925Table I: genomic Disclosures: Leleu: CELGENE: Honoraria; JANSSEN: Honoraria. Moreau:Celgene: Honoraria, Speakers Bureau. Avet-Loiseau:CELGENE: Honoraria, Speakers Bureau; JANSSEN: Honoraria, Speakers Bureau." @default.
• W2212292700 created "2016-06-24" @default.
• W2212292700 creator A5000761302 @default.
• W2212292700 creator A5005665639 @default.
• W2212292700 creator A5006646662 @default.
• W2212292700 creator A5008156104 @default.
• W2212292700 creator A5014942120 @default.
• W2212292700 creator A5015832963 @default.
• W2212292700 creator A5026970655 @default.
• W2212292700 creator A5027311948 @default.
• W2212292700 creator A5029315909 @default.
• W2212292700 creator A5035919558 @default.
• W2212292700 creator A5041002394 @default.
• W2212292700 creator A5041108107 @default.
• W2212292700 creator A5045552922 @default.
• W2212292700 creator A5048560248 @default.
• W2212292700 creator A5059170395 @default.
• W2212292700 creator A5060956664 @default.
• W2212292700 creator A5063422967 @default.
• W2212292700 creator A5064361769 @default.
• W2212292700 creator A5069447323 @default.
• W2212292700 creator A5069449708 @default.
• W2212292700 creator A5069745915 @default.
• W2212292700 creator A5069931312 @default.
• W2212292700 creator A5075950291 @default.
• W2212292700 creator A5089853890 @default.
• W2212292700 date "2013-11-15" @default.
• W2212292700 modified "2023-09-30" @default.
• W2212292700 title "First Large Prospective Study For Patients With Primary Plasma Cell Leukemia: Bortezomib-Doxorubicine-Dexamethasone/Bortezomib-Cyclophosphamide-Dexamethasone Regimens As Induction Before Stem Cell Transplantation Followed By Consolidation With Lenalidomide-Bortezomib-Dex Or Allograft. (a study of the IFM group)" @default.
• W2212292700 doi "https://doi.org/10.1182/blood.v122.21.761.761" @default.
• W2212292700 hasPublicationYear "2013" @default.
• W2212292700 type Work @default.
• W2212292700 sameAs 2212292700 @default.
• W2212292700 citedByCount "2" @default.
• W2212292700 countsByYear W22122927002014 @default.
• W2212292700 countsByYear W22122927002016 @default.
• W2212292700 crossrefType "journal-article" @default.
• W2212292700 hasAuthorship W2212292700A5000761302 @default.
• W2212292700 hasAuthorship W2212292700A5005665639 @default.
• W2212292700 hasAuthorship W2212292700A5006646662 @default.
• W2212292700 hasAuthorship W2212292700A5008156104 @default.
• W2212292700 hasAuthorship W2212292700A5014942120 @default.
• W2212292700 hasAuthorship W2212292700A5015832963 @default.
• W2212292700 hasAuthorship W2212292700A5026970655 @default.
• W2212292700 hasAuthorship W2212292700A5027311948 @default.
• W2212292700 hasAuthorship W2212292700A5029315909 @default.
• W2212292700 hasAuthorship W2212292700A5035919558 @default.
• W2212292700 hasAuthorship W2212292700A5041002394 @default.
• W2212292700 hasAuthorship W2212292700A5041108107 @default.
• W2212292700 hasAuthorship W2212292700A5045552922 @default.
• W2212292700 hasAuthorship W2212292700A5048560248 @default.
• W2212292700 hasAuthorship W2212292700A5059170395 @default.
• W2212292700 hasAuthorship W2212292700A5060956664 @default.
• W2212292700 hasAuthorship W2212292700A5063422967 @default.
• W2212292700 hasAuthorship W2212292700A5064361769 @default.
• W2212292700 hasAuthorship W2212292700A5069447323 @default.
• W2212292700 hasAuthorship W2212292700A5069449708 @default.
• W2212292700 hasAuthorship W2212292700A5069745915 @default.
• W2212292700 hasAuthorship W2212292700A5069931312 @default.
• W2212292700 hasAuthorship W2212292700A5075950291 @default.
• W2212292700 hasAuthorship W2212292700A5089853890 @default.
• W2212292700 hasConcept C126322002 @default.
• W2212292700 hasConcept C126894567 @default.
• W2212292700 hasConcept C141071460 @default.
• W2212292700 hasConcept C143998085 @default.
• W2212292700 hasConcept C2776063141 @default.
• W2212292700 hasConcept C2776364478 @default.
• W2212292700 hasConcept C2776694085 @default.
• W2212292700 hasConcept C2776755627 @default.
• W2212292700 hasConcept C2777478702 @default.
• W2212292700 hasConcept C2778684742 @default.
• W2212292700 hasConcept C2779050716 @default.
• W2212292700 hasConcept C2780353925 @default.
• W2212292700 hasConcept C2780401358 @default.
• W2212292700 hasConcept C2911091166 @default.
• W2212292700 hasConcept C71924100 @default.
• W2212292700 hasConcept C90924648 @default.
• W2212292700 hasConceptScore W2212292700C126322002 @default.
• W2212292700 hasConceptScore W2212292700C126894567 @default.
• W2212292700 hasConceptScore W2212292700C141071460 @default.
• W2212292700 hasConceptScore W2212292700C143998085 @default.
• W2212292700 hasConceptScore W2212292700C2776063141 @default.
• W2212292700 hasConceptScore W2212292700C2776364478 @default.
• W2212292700 hasConceptScore W2212292700C2776694085 @default.
• W2212292700 hasConceptScore W2212292700C2776755627 @default.
• W2212292700 hasConceptScore W2212292700C2777478702 @default.
• W2212292700 hasConceptScore W2212292700C2778684742 @default.
• W2212292700 hasConceptScore W2212292700C2779050716 @default.
• W2212292700 hasConceptScore W2212292700C2780353925 @default.
• W2212292700 hasConceptScore W2212292700C2780401358 @default.
• W2212292700 hasConceptScore W2212292700C2911091166 @default.
• W2212292700 hasConceptScore W2212292700C71924100 @default.
• W2212292700 hasConceptScore W2212292700C90924648 @default.
• W2212292700 hasLocation W22122927001 @default.
• W2212292700 hasOpenAccess W2212292700 @default.
• W2212292700 hasPrimaryLocation W22122927001 @default.
• W2212292700 hasRelatedWork W2068579037 @default.
• W2212292700 hasRelatedWork W2091967130 @default.
• W2212292700 hasRelatedWork W2336472643 @default.
• W2212292700 hasRelatedWork W2521999181 @default.

• next